Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; hydrochloric acid; benzoic acid; purified water - risperidone bnm is indicated for the treatment of schizophrenia and related psychoses.,risperidone bnm is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,risperidone bnm is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,risperidone bnm is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,risperidone bnm is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 10 mg/ml - oral liquid, powder for - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; sodium benzoate; xanthan gum; colloidal anhydrous silica; titanium dioxide; flavour - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see adverse reactions). diflucan iv is indicated for the same conditions in adults and children but should be used only when diflucan cannot be administered orally.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - dibasic sodium phosphate, quantity: 4.3 g; monobasic sodium phosphate, quantity: 18.8 g - oral liquid - excipient ingredients: glycerol; saccharin sodium; sodium benzoate; purified water; flavour - for use as part of a bowel cleansing regimen in preparing adult patients for colon surgery or for preparing the colon for x-ray or endoscopic examination.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - deferiprone, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: glycerol; hydrochloric acid; sucralose; sunset yellow fcf; peppermint oil; hyetellose; purified water; flavour - indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy; or in whom desferrioxamine therapy has proven ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - deferiprone, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucralose; purified water; glycerol; sunset yellow fcf; hydrochloric acid; hyetellose; peppermint oil; flavour - indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy; or in whom desferrioxamine therapy has proven ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 10 mg/ml - oral solution - 10 mg/ml - active: methadone hydrochloride 10 mg/ml excipient: brilliant blue fcf cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 1 mg/ml - oral solution - 1 mg/ml - active: methadone hydrochloride 1 mg/ml excipient: brilliant blue fcf cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate tartrazine xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 5 mg/ml - oral solution - 5 mg/ml - active: methadone hydrochloride 5 mg/ml excipient: caramel cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.